OXT and Hyperbilirubinemia: The findings suggest that obstetricians should consider both oxytocin dose and neonatal risk when administering the drug, avoiding prolonged or high-dose exposure, particularly above ∼15 IU, and monitoring neonatal serum bilirubin closely in such cases to reduce the incidence of hyperbilirubinemia and related complications.